The metabolism of siRNA is predominantly driven by nuclease-mediated degradation. Both endonucleases and exonucleases cleave the phosphodiester backbone of the oligonucleotide, breaking it down into smaller, inactive fragments. This process occurs systemically and within target tissues, primarily the liver and kidneys.

The delivery vehicle is a primary determinant of the siRNA’s pharmacokinetic profile. Lipid nanoparticles (LNPs) are engineered to target hepatocytes, fundamentally altering the biodistribution away from rapid renal filtration. This directs the LNP-siRNA complex to the liver, where clearance is managed by the reticuloendothelial system, influencing both the rate and route of excretion.

A multi-platform approach is required. Quantitative PCR (qPCR) and hybridization-based ligand binding assays (LBAs) are effective for quantifying the parent oligonucleotide. For characterizing and quantifying metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS) provides the necessary specificity and sensitivity to differentiate between the full-length siRNA and its degradation products.

Defining the routes and rates of elimination is foundational to building a robust safety profile. This data informs the potential for accumulation in non-target tissues, assesses the risk of toxicity from stable metabolites, and helps establish a well-supported safety margin before advancing to first-in-human studies.